Pallav K. Mehta MD
Director of Integrative Oncology, MD Anderson at Cooper
- Board certified in medical oncology, hematology, and integrative medicine
- Author of several journal articles, reviews, and clinical trials, in which he has served as both author and as a local principal investigator
- Has developed a broad integrative medicine initiative aimed at people with cancer
Connect with Dr. Mehta
Pallav Mehta, MD, is a medical oncologist/hematologist with expertise and interest in breast cancer and integrative oncology and is board certified in medical oncology, hematology, and integrative medicine. He is the director of integrative oncology and practice development at the MD Anderson Cancer Center at Cooper in Camden, New Jersey and an assistant professor of medicine, division of hematology/oncology at Cooper Medical School, Rowan University. He is a member of Living Beyond Breast Cancer’s board of directors.
Dr. Mehta is also chief of the division of hematology and oncology and the medical director of the COC-accredited Charles A. and Betty Bott Cancer Center at Holy Redeemer Hospital in Meadowbrook, Pennsylvania, now a collaborating partner for MD Anderson Cancer Center and MD Anderson Cancer Center at Cooper. He is the cancer liaison physician to the Commission on Cancer for Holy Redeemer Hospital and is also a faculty lecturer at Cooper Medical School. He has authored several journal articles, reviews, and clinical trials, in which he has served as both author and as local principal investigator. He also developed a broad integrative medicine initiative aimed at people with cancer.
Dr. Mehta has been invited to speak nationally on the topic of exercise and cancer and serves as a consultant and speaker for several international oncology-related companies pertaining to breast cancer, genetics, and molecular profiling. He is co-author of After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients After Cancer, published in 2015, Rodale Inc.
The relationship that is developed between a patient and their oncologist is one that is unique in all of medicine. I truly appreciate and enjoy the opportunity to guide my patients through what is often a frightening and life-changing experience. I firmly believe in utilizing standard of care and cutting-edge cancer therapies, while also understanding the importance of the patient as a human being, incorporating topics such as optimizing nutrition or exercise with every patient I meet. I am always grateful that this wonderful profession provides me with personal and professional fulfillment at every level.
Experience & Accolades
- Medical Oncology, Hematology
- Fox Chase Cancer Center
- Fellowship, Hematology/Oncology
- Temple University Hospital
- Internship and Residency, Internal Medicine
- Sidney Kimmel Medical College of Thomas Jefferson University
- Doctor of Medicine
- New York University
- Bachelor's of Science - Biology
Awards and Distinctions
- Castle Connolly Regional Top Doctors 1st Edition
- Philadelphia Magazine Top Docs (2018, 2019, 2020)
- Jersey's Best Magazine Top Doctors (2017, 2018, 2019)
- Jersey's Best Magazine Top Doctors for Women's Health (2018)
- Jersey's Best Magazine Top Doctors for Cancer (2017, 2018, 2019)
Professional Memberships and Board Positions
Metastatic breast cancer symptoms
Metastatic breast cancer can cause a range of symptoms, and not every person experiences them in exactly the same way. On this page, you can learn about common metastatic breast cancer symptoms, and we’ll share links to more detailed information.
COVID-19 vaccine boosters for people in breast cancer treatment, with Pallav Mehta, MD
Living Beyond Breast Cancer CEO Jean A. Sachs, MSS, MLSP, speaks with medical oncologist Pallav Mehta, MD, about who is eligible for a COVID-19 booster shot, whom to ask if you think you should get a booster, and how medical centers are adapting to recommendations.
Healthcare provider perspective: It’s a marathon
Pallav K. Mehta, MD, spoke with LBBC about the changes he’s seen in 15 years of treating metastatic hormone receptor-positive breast cancer, and what people should know about their diagnosis and treatment.
FDA Approval Programs
Studies can take years to prove the effects of a medicine. The FDA’s review adds more time to the process, but the agency does have programs to help important medicines move through the process – and become available to people who need them – more quickly.
Lapatinib (Tykerb) is targeted therapy in the dual tyrosine kinase inhibitor class. It is used with the chemotherapy pill capecitabine (Xeloda) or the aromatase inhibitor letrozole (Femara) to treat HER2-positive metastatic breast cancer after treatment with other medicines.
Goals of treatment
The goal of treatment in metastatic breast cancer is to prevent or slow progression of the disease while easing your symptoms and treatment side effects. Your healthcare team will be focused on enhancing your overall well-being while working to reduce the amount of cancer in your body.